指南与共识炎症性肠病

选择炎症性肠病疾病修饰试验的终点:IOIBD的SPIRIT共识

Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD.
指南 / 共识 · Gastroenterology · 2021-01-06

SPIRIT倡议由国际炎症性肠病研究组织(IOIBD)发起,旨在就未来IBD疾病修饰试验的终点达成国际专家共识。通过系统文献检索和2019年UEGW会议上的匿名投票(共识定义为≥75%参与者同意),专家组一致认为CD和UC的最终治疗目标是预防疾病对患者生活的影响、中期并发症和长期并发症。这些推荐需在实际临床研究中验证后才能用于疾病修饰试验。

要点

  • CD和UC疾病修饰试验的最终目标是预防疾病对患者生活的影响。
  • 中期并发症包括CD的肠道损伤、IBD相关手术和住院、UC的疾病扩展等。
  • 长期并发症包括胃肠道及肠外发育不良或癌症和死亡。

核心结论

  • SPIRIT共识提出了IBD疾病修饰试验中预防疾病进展应达到的目标推荐。
  • 这些推荐需在实际临床研究中验证后方可用于疾病修饰试验。

研究设计与样本

  • IOIBD主持的共识倡议,先进行系统文献检索评估IBD疾病进展定义的当前证据。
  • 共识定义为至少75%参与者投票同意任一声明。

主要发现

  • 专家组一致认为CD和UC的最终治疗目标是预防疾病对患者生活的影响(健康相关生活质量、残疾、大便失禁)。
  • 中期并发症包括CD的肠道损伤、IBD相关手术和住院、UC的疾病扩展、肠外表现、永久性造口、短肠综合征。
  • 长期并发症包括胃肠道和肠外发育不良或癌症、死亡。

关键数值与推荐

  • 共识达成阈值为至少75%参与者投票同意任一声明。

临床怎么用

  • 在设计和开展IBD疾病修饰试验时,可参考SPIRIT共识选择以预防疾病影响、中期并发症和长期并发症为目标的终点。
  • 共识推荐在用于疾病修饰试验前需在实际临床研究中验证。

局限性

  • 推荐需在实际临床研究中验证后方可实施于疾病修饰试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are chronic and disabling disorders. Prospective disease-modification trials to prevent disease progression are eagerly awaited. However, disease progression is not clearly defined. The objective of the Selecting End PoInts foR Disease-ModIfication Trials (SPIRIT) initiative was to achieve international expert consensus on the endpoints to be used in future IBD-disease modification trials. METHODS: This initiative under the auspices of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) began with a systematic literature search to evaluate the current evidence on the definition of disease progression in IBD. On October 22, 2019, a consensus meeting took place during the United European Gastroenterology Week (UEGW) Congress in Barcelona, during which predefined proposed statements were discussed in a plenary session and voted on anonymously. Agreement was defined as at least 75% of participants voting for any one statement. RESULTS: The group agreed that the ultimate therapeutic goal in both CD and UC is to prevent disease impact on patient's life (health-related quality of life, disability, fecal incontinence), midterm complications (encompass bowel damage in CD, IBD-related surgery and hospitalizations, disease extension in UC, extraintestinal manifestations, permanent stoma, short bowel syndrome), and long-term complications (gastrointestinal and extraintestinal dysplasia or cancer, mortality). CONCLUSIONS: Recommendations on which goals to achieve in disease-modification trials for preventing disease progression in patients with IBD are proposed by the SPIRIT consensus. However, these recommendations will require validation in actual clinical studies before implementation in disease-modification trials.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Le Berre C, Peyrin-Biroulet L. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology. 2021. PMID: 33421515. doi:10.1053/j.gastro.2020.10.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。